(April 6, 2016, 11:54 AM EDT) -- PHILADELPHIA — Janssen Pharmaceuticals Inc. and Johnson & Johnson on April 1 said they will appeal a Risperdal gynecomastia verdict, even after the court on March 10 reduced the original $1.75 million award to a statutory maximum of $680,000 (Nicholas Murray v. Janssen Pharmaceuticals, Inc., et al., No. 130401990, Pa. Comm. Pls., Philadelphia Co.)....